{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:37:32Z","timestamp":1792517852685,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014489","name":"Johnson & Johnson Pharmaceutical Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.013","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:52:49Z","timestamp":1777333969000},"page":"423-435.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-ICANS Neurologic Events in Patients With Relapsed\/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"G\u00e1llego P\u00e9rez-Larraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenos L.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-min","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreta","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Montes de Oca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Plaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Taraseviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Jethava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Jablow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Afifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythili","family":"Koneru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca D.","family":"Santomasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.04.013_bib0001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.04.013_bib0002","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.013_bib0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.04.013_bib0004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0005","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of Cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.04.013_bib0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clml.2022.10.001","article-title":"Patient perceptions regarding ciltacabtagene autoleucel treatment: qualitative evidence from interviews with patients with relapsed\/refractory multiple myeloma in the CARTITUDE-1 study","volume":"23","author":"Cohen","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.04.013_bib0007","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood-2024-201783","article-title":"Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG Registry","volume":"144","author":"Kumar","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0008","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.04.013_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2026.04.013_bib0010","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/ph17081025","article-title":"Comparing the differences in adverse events among chimeric antigen receptor T-cell therapies: a real-world pharmacovigilance study","volume":"17","author":"Guo","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clml.2026.04.013_bib0011","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0012","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (>\/=5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.013_bib0013","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S2152-2650(24)02346-2","article-title":"OA-65 overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SoC) in lenalidomide (Len)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update","volume":"24","author":"Mateos","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.04.013_bib0014","series-title":"Prescribing Information","year":"2024"},{"key":"10.1016\/j.clml.2026.04.013_bib0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41408-025-01410-w","article-title":"Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed\/refractory MM in CARTITUDE-1, -2, and -4","volume":"15","author":"Rodr\u00edguez-Otero","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.04.013_bib0016","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2023-178882","article-title":"The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)","volume":"142","author":"Hillengass","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0017","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S2152-2650(24)01853-6","article-title":"OA-12 Interim phase 2 study results of durcabtagene autoleucel (PHE885), a T-Charge\u2122 manufactured BCMA-directed CAR-T cell therapy in patients (pts) with r\/r multiple myeloma (RRMM)","volume":"24","author":"Spencer","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.04.013_bib0018","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S2152-2650(24)01905-0","article-title":"P-002 Ide-cel real-world (RW) and clinical trial long-term safety experience: a special focus on movement and neurocognitive treatment adverse events (MNT AEs) and second primary malignancies (SPMs)","volume":"24","author":"Abonour","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.04.013_bib0019","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world Chimeric Antigen Receptor Consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.013_bib0020","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.04.013_bib0021","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.013_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.04.013_bib0023","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1182\/blood-2025-4596","article-title":"Real-world incidence and management of non-ICANS neurologic events following ciltacabtagene autoleucel in multiple myeloma","volume":"146","author":"Hansen","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0024","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024028172","article-title":"Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment","volume":"145","author":"Blumenberg","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0025","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.04.013_bib0026","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1200\/JCO.2024.42.16_suppl.7535","article-title":"Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup","volume":"42","author":"Cohen","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.013_bib0027","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0028","doi-asserted-by":"crossref","first-page":"71.e1","DOI":"10.1016\/j.jtct.2024.12.002","article-title":"Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data","volume":"31","author":"Ellithi","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.04.013_bib0029","unstructured":"U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS) public dashboard for drugs and biologics. Available at: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis. Accessed: September 22, 2025."},{"key":"10.1016\/j.clml.2026.04.013_bib0030","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2026.04.013_bib0031","series-title":"Corticosteroid Induced Myopathy","article-title":"In: StatPearls","author":"Surmachevska","year":"2023"},{"key":"10.1016\/j.clml.2026.04.013_bib0032","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-024-01107-6","article-title":"IgG replacement in multiple myeloma","volume":"14","author":"Wonnaparhown","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.04.013_bib0033","first-page":"692","article-title":"The diagnosis and treatment of idiopathic facial paresis (Bell\u2019s palsy)","volume":"116","author":"Heckmann","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clml.2026.04.013_bib0034","doi-asserted-by":"crossref","first-page":"94","DOI":"10.18773\/austprescr.2017.030","article-title":"Management of Bell\u2019s palsy","volume":"40","author":"Somasundara","year":"2017","journal-title":"Aust Prescr"},{"key":"10.1016\/j.clml.2026.04.013_bib0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bjoms.2014.03.001","article-title":"Evidence based management of Bell\u2019s palsy","volume":"52","author":"McCaul","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.clml.2026.04.013_bib0036","first-page":"S1","article-title":"Clinical practice guideline: Bell\u2019s palsy","volume":"149","author":"Baugh","year":"2013","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.clml.2026.04.013_bib0037","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S2152-2650(25)03493-7","article-title":"Evaluation of sequential absolute lymphocyte count (ALC) in patients with relapsed multiple myeloma (RRMM) with cranial nerve palsies (CNPs) post ciltacabtagene-autoleucel (cilta-cel)","volume":"25","author":"Salva","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.04.013_bib0038","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2023-178743","article-title":"Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)","volume":"142","author":"Van De Donk","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0039","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1007\/s00415-019-09282-4","article-title":"The etiology of Bell\u2019s palsy: a review","volume":"267","author":"Zhang","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.clml.2026.04.013_bib0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-025-01441-3","article-title":"Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma","volume":"16","author":"Lim","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.04.013_bib0041","unstructured":"StatPearls. Parkinsonism. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542224\/. Accessed: March 23, 2025."},{"key":"10.1016\/j.clml.2026.04.013_bib0042","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41531-021-00185-8","article-title":"Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis","volume":"7","author":"Bega","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.clml.2026.04.013_bib0043","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JPD-150733","article-title":"Clinical application of brain MRI in the diagnostic work-up of parkinsonism","volume":"7","author":"Meijer","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.clml.2026.04.013_bib0044","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.04.013_bib0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy","volume":"70","author":"Marella","year":"2022","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.clml.2026.04.013_bib0046","series-title":"Presented at: EHA-EBMT 7th European CAR T-cell Meeting","article-title":"Movement and neurocognitive treatment-emergent adverse event (MNT) after CD19-directed CAR T-cell therapy","author":"Schroeder","year":"2025"},{"key":"10.1016\/j.clml.2026.04.013_bib0047","article-title":"Treatment-Emergent Parkinsonism in Four Patients Treated with Chimeric Antigen Receptor T-Cell Therapy","author":"Sanderson","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.clml.2026.04.013_bib0048","series-title":"Prescribing Information","year":"2024"},{"key":"10.1016\/j.clml.2026.04.013_bib0049","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1002\/hem3.131","article-title":"Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel","volume":"8","author":"Couturier","year":"2024","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2026.04.013_bib0050","doi-asserted-by":"crossref","first-page":"v152","DOI":"10.1093\/neuonc\/noad179.0577","article-title":"IMMU-45. Reversible parkinsonism after BCMA-directed CAR T cell administration","volume":"25","author":"Gewirtz","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.clml.2026.04.013_bib0051","first-page":"2443","article-title":"How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity","volume":"141","author":"Santomasso","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0052","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jamaneurol.2024.2506","article-title":"Parkinsonism following chimeric antigen receptor T cell therapy","volume":"81","author":"Gudera","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.clml.2026.04.013_bib0053","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2025-2215","article-title":"Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma","volume":"146","author":"Dhakal","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0054","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","article-title":"Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma","volume":"8","author":"Mejia Saldarriaga","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.04.013_bib0055","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.jtct.2025.01.330","article-title":"Prophylactic dexamethasone rescues unrestrained lymphocyte expansion in anti-BCMA chimeric antigen receptor T cell therapy in multiple myeloma","volume":"31","author":"Turner","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.04.013_bib0056","series-title":"Presented at: European Haematology Association Hybrid Congress","article-title":"Absolute lymphocyte count as a key biomarker for monitoring safety after ciltacabtagene autoleucel","author":"Lin","year":"2025"},{"key":"10.1016\/j.clml.2026.04.013_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1444010","article-title":"Case report: treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen","volume":"15","author":"Aliakbar","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2026.04.013_bib0058","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.04.013_bib0059","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/mdc3.14335","article-title":"Parkinsonism and bilateral facial palsy after chimeric antigen receptor T-cell therapy","volume":"12","author":"Wu","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.clml.2026.04.013_bib0060","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1182\/bloodadvances.2024015721","article-title":"Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity","volume":"9","author":"Kelly","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.04.013_bib0061","doi-asserted-by":"crossref","first-page":"v68","DOI":"10.1093\/neuonc\/noae144.223","article-title":"P12.10.B hypokinetic movement disorders following adoptive immunotherapy with BCMA-directed CAR T-cells: a consecutive case series","volume":"26","author":"Gudera","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.clml.2026.04.013_bib0062","doi-asserted-by":"crossref","first-page":"S498","DOI":"10.1016\/j.jtct.2025.01.792","article-title":"Late neurotoxicity after chimeric antigen receptor T cell therapy; the advanced practice professional and nursing approach to diagnosis and management","volume":"31","author":"Velez","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.04.013_bib0063","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/mdc3.14239","article-title":"Parkinsonism associated with anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy","volume":"11","author":"Schneider","year":"2024","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.clml.2026.04.013_bib0064","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1182\/blood-2025-5856","volume":"146","author":"Feliciano Salva","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0065","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1182\/blood-2025-5953","article-title":"Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity","volume":"146","author":"Lim","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0066","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-024-01048-0","article-title":"Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"14","author":"Costa","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.04.013_bib0067","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2021-146678","article-title":"Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma","volume":"138","author":"Duvalyan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0068","article-title":"Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed\/refractory multiple myeloma treated with CAR-T therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2026.04.013_bib0069","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","article-title":"Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids","volume":"59","author":"Oluwole","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.04.013_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1398078","article-title":"Overview of infectious complications among CAR T-cell therapy recipients","volume":"14","author":"Arya","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.04.013_bib0071","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.04.013_bib0072","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.013_bib0073","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.04.013_bib0074","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.04.013_bib0075","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/S2152-2650(24)01993-1","article-title":"P-090 infections and immune reconstitution in the phase 3 CARTITUDE-4 trial of ciltacabtagene autoleucel vs standard care in patients with lenalidomide-refractory multiple myeloma (MM) and 1\u20133 prior lines","volume":"24","author":"van de Donk","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:52:50Z","timestamp":1785963170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001138"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-ICANS Neurologic Events in Patients With Relapsed\/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}